Biocartis Group NV (LTS:0R72) Other Financing: €23.00 Mil (TTM As of Jun. 2023)


LTS:0R72 Biocartis Group NV LTS:0R72
14 GF Score
Price €0.30
View Full Analysis

What is Biocartis Group NV Other Financing?

Biocartis Group NV LTS:0R72 14 Other Financing is €23.00 Mil as of Jun. 2023. GuruFocus rates LTS:0R72 with a GF Score™ of 14/100.

Biocartis Group NV's Other Financing for the six months ended in Jun. 2023 was €-0.03 Mil.

Biocartis Group NV's Other Financing for the trailing twelve months (TTM) ended in Jun. 2023 was €23.00 Mil.

Biocartis Group NV Other Financing Historical Data

* Premium members only.

The historical data trend for Biocartis Group NV's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocartis Group NV Other Financing Chart

Biocartis Group NV Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.04 -4.36 -0.12 -0.07

Biocartis Group NV Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.05 -0.04 23.03 -0.03
LTS:0R72
14GF Score
Biocartis Group NV LTS:0R72
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocartis Group NV Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €23.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €23.00 Mil mean?
Biocartis Group NV (LTS:0R72) has a Other Financing of €23.00 Mil as of Jun. 2023. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Biocartis Group NV and its competitors.
Is Biocartis Group NV's Other Financing too high?
Biocartis Group NV's current Other Financing is €23.00 Mil. Overall, Biocartis Group NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Biocartis Group NV's Other Financing compare to TMO and DHR?
Biocartis Group NV's Other Financing of €23.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Diagnostics & Research company?
A good Other Financing depends on the Medical Diagnostics & Research industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Biocartis Group NV and its competitors. Biocartis Group NV's current Other Financing is €23.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocartis Group NV stock overvalued right now?
Biocartis Group NV (LTS:0R72) has a current Other Financing of €23.00 Mil. The current Other Financing is €23.00 Mil. Biocartis Group NV's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Biocartis Group NV (LTS:0R72), the current Other Financing is €23.00 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biocartis Group NV Business Description

Address Generaal de Wittelaan 11 B, Mechelen, BEL, 2800
Biocartis Group NV is a commercial-stage molecular diagnostics company. It provides diagnostic solutions aimed at improving clinical practice for patients, clinicians, payers, and the industry. The firm has developed an Meet Idylla molecular diagnostic system for oncology and infectious disease segments.
14GF Score

Get the complete analysis for LTS:0R72

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.30
Price